4.7 Article

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation The ISAR-TRIPLE Trial

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 65, 期 16, 页码 1619-1629

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.02.050

关键词

aspirin; atrial fibrillation; clopidogrel; percutaneous coronary intervention; vitamin K antagonist

资金

  1. Abbott
  2. Deutsches Herzzentrum Munchen
  3. PCI Research at Aarhus University Hospital
  4. Eli Lilly
  5. Daiichi-Sankyo
  6. Bayer Vital
  7. AstraZeneca
  8. Verum Diagnostica
  9. Roche Diagnostics
  10. Medtronic
  11. Sanofi
  12. Medicines Company
  13. SERVIER
  14. Boehringer-Ingelheim
  15. MSD Sharp Dohme
  16. Berlin-Chemie
  17. Biosensors
  18. Biotronik
  19. MSD
  20. Lilly/Daiichi-Sankyo
  21. Boehringer Ingelheim
  22. Bayer Healthcare
  23. Boston Scientific
  24. Novo Nordisk Fonden [NNF14OC0008817] Funding Source: researchfish

向作者/读者索取更多资源

BACKGROUND Patients receiving oral anticoagulation (OAC) who undergo drug-eluting stent (DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel. Such triple therapy confers an elevated bleeding risk, and its optimal duration is not known. OBJECTIVES The goal of this study was to evaluate whether shortening the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation was associated with a superior net clinical outcome in patients receiving concomitant aspirin and OAC. METHODS In this randomized, open-label trial, we enrolled patients receiving OAC who underwent DES implantation at 3 European centers between September 2008 and December 2013. A total of 614 patients receiving concomitant aspirin and OAC were randomized to either 6-week clopidogrel therapy (n = 307) or 6-month clopidogrel therapy (n = 307). The primary endpoint was a composite of death, myocardial infarction (MI), definite stent thrombosis, stroke, or Thrombolysis In Myocardial Infarction (TIMI) major bleeding at 9 months. RESULTS The primary endpoint occurred in 30 patients (9.8%) in the 6-week group compared with 27 patients (8.8%) in the 6-month group (hazard ratio [HR]: 1.14; 95% CI: 0.68 to 1.91; p = 0.63). There were no significant differences for the secondary combined ischemic endpoint of cardiac death, MI, definite stent thrombosis, and ischemic stroke (12 [4.0%] vs. 13 [4.3%]; HR: 0.93; 95% CI: 0.43 to 2.05; p = 0.87) or the secondary bleeding endpoint of TIMI major bleeding (16 [5.3%] vs. 12 [4.0%]; HR: 1.35; 95% CI: 0.64 to 2.84; p = 0.44). CONCLUSIONS Six weeks of triple therapy was not superior to 6 months with respect to net clinical outcomes. These results suggest that physicians should weigh the trade-off between ischemic and bleeding risk when choosing the shorter or longer duration of triple therapy. (C) 2015 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据